耐多药结核病患者较短的 MDR-TB 方案的结局和依从性。
Outcomes and adherence of shorter MDR TB regimen in patients with multidrug resistant tuberculosis.
机构信息
Guntur Medical College, Guntur, India.
NIMS, Hyderabad, India.
出版信息
Indian J Tuberc. 2023 Jan;70(1):103-106. doi: 10.1016/j.ijtb.2022.03.021. Epub 2022 Apr 1.
BACKGROUND
In 2016 WHO guidelines conditionally recommended standardized shorter 9-12 months regimen for MDR-TB treatment. The objective is to study outcome analysis of cured, lost to follow-up, treatment completed, treatment failure and mortality of MDR Patients on shorter standardized MDR TB regimen.
METHODS
In this prospective study, 360 adults with confirmed Rifampicin Resistant pulmonary TB were studied between March 2018 to February 2020 at Department of Pulmonary Medicine, Guntur Medical College, Govt. Fever Hospital, Guntur.
RESULTS
Among 360 confirmed MDR Patients, 42.50% patients were cured, 41.60% completed treatment, 6.11% of them were lost to follow-up, 0.50% were considered as treatment failure and 9.10% of them were died.
CONCLUSION
Overall success with a standardized shorter MDR regimen was high with low treatment failure. When introducing shorter regimens base line drug susceptibility testing and minimizing missed doses are critical.
背景
2016 年世卫组织有条件地推荐了标准化的、时长为 9-12 个月的耐多药结核病治疗方案。本研究旨在分析采用标准化短程方案治疗耐多药结核病患者的治愈、失访、治疗完成、治疗失败和死亡率等结局。
方法
在这项前瞻性研究中，2018 年 3 月至 2020 年 2 月，我们在贡土尔医学院肺部医学系、政府发热医院对 360 名确诊的利福平耐药性肺结核成人患者进行了研究。
结果
在 360 例确诊的耐多药患者中，42.50%的患者治愈，41.60%完成治疗，6.11%失访，0.50%治疗失败，9.10%死亡。
结论
采用标准化短程方案治疗的总体成功率较高，治疗失败率较低。引入更短的治疗方案时，基线药物敏感性测试和尽量减少漏服剂量至关重要。
Zotero 插件